Financial Analysis: ABIOMED (ABMD) & Its Peers
ABIOMED (NASDAQ: ABMD) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare ABIOMED to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Institutional & Insider Ownership
89.7% of ABIOMED shares are held by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 7.0% of ABIOMED shares are held by company insiders. Comparatively, 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares ABIOMED and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ABIOMED||$474.78 million||$110.92 million||102.87|
|ABIOMED Competitors||$2.02 billion||$430.74 million||-69.00|
ABIOMED’s peers have higher revenue and earnings than ABIOMED. ABIOMED is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings for ABIOMED and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ABIOMED presently has a consensus price target of $174.71, suggesting a potential upside of 0.50%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.95%. Given ABIOMED’s stronger consensus rating and higher possible upside, equities research analysts clearly believe ABIOMED is more favorable than its peers.
Risk & Volatility
ABIOMED has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, ABIOMED’s peers have a beta of 0.89, indicating that their average share price is 11% less volatile than the S&P 500.
This table compares ABIOMED and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ABIOMED beats its peers on 8 of the 13 factors compared.
ABIOMED Company Profile
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.